RxDoctor Payments Data

Ashley Zinda, DO

Cardiovascular Disease · Hanover, PANPI 1588978506

Payments from drug & device makers

$628in general payments, 2019–2025

Across 27 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$211
  • Abbott$143
  • Lantheus Medical Imaging, Inc.$60
  • Novartis$49
  • Sanofi-aventis U.S. LLC$34
  • Johnson & Johnson$29
  • plus $102 from 5 others

What the payments were for

  • Food & beverage$628100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$628 in reported general payments places this provider in the 30th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$223,829
Medicare patients
2,549
Services billed
5,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban512$550,481
EntrestoSacubitril/Valsartan82$94,385
Repatha SureclickEvolocumab92$79,730
XareltoRivaroxaban61$63,474
JardianceEmpagliflozin72$53,175
FarxigaDapagliflozin Propanediol11$7,445
Metoprolol Succinate600$7,400
Ezetimibe203$3,972
Atorvastatin Calcium361$3,011
Diltiazem 24hr Er (Cd)Diltiazem Hcl73$2,000
Bumetanide51$1,977
Furosemide413$1,919
Amlodipine Besylate219$1,883
Metoprolol Tartrate262$1,716
Flecainide Acetate42$1,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$550,481512 claims
NovartisEntresto$49$94,38582 claims
Johnson & JohnsonXarelto$29$63,47461 claims
Boehringer IngelheimJardiance$14$53,17572 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Hanover

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →